Metastasis prevention with bone-targeted agents: a complex interaction between the microenvironment and tumour biology.

Adjuvant bisphosphonates are now part of standard clinical guidelines for postmenopausal women with early breast cancer at intermediate to high risk of recurrence. MAF testing of primary tumours may improve patient selection for treatment.